Retina

Insights on injection technique and the future potential of SCS treatments.

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently with no current FDA-approved therapy

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials

Intracameral tPA can treat fibrinous clots in severe anterior uveitis.

Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

High-resolution optical coherence tomography illuminates crucial biomarkers in age-related macular degeneration, Dr Sadda said

Looking at innovative tools and their applications in different disease states can help to think creatively about ways to benefit patients in retina care.

FLIO ushers clinicians from structural to functional imaging, said Robert Sergott, MD, in a presentation at the International SPECTRALIS Symposium

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related macular degeneration, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Advanced monitoring strategies are overcoming significant obstacles in retinal care, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.

Fluorescence lifetime imaging ophthalmoscopy is emerging as a valuable tool to reveal previously hidden links between retinal changes and systemic disease.

The phase 2/3 clinical trial for OCU410ST will enroll 51 participants diagnosed with Stargardt disease.

A study reveals significant retinal vessel changes in diabetic retinopathy, highlighting the need for early detection methods to prevent vision loss.

The LYNX LIO is the latest generation of pattern scanning lasers that were first introduced in 2006.

Prof Baljean Dhillon advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium

Anat Loewenstein, MD, presented real-world results of remote imaging at the International SPECTRALIS Symposium

Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture

Advanced autofluorescence reveals cellular pigment reservoirs with therapeutic potential at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Dr Brunstetter, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, delivered the lecture at this year's ISS alongside his colleague Warren Hoburg

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium